research Dupilumab: Friend or Foe to Alopecia Areata?
Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.
Search
for
Sort by
Research
60-90 / 437 results 
research 20 Exosomes derived from adipose tissue-derived mesenchymal stem cells (ASCE) for the treatment of dupilumab-related facial redness in patients with atopic dermatitis
Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.
research 272 Dupilumab treatment in children with alopecia areata: A real-world, single-center observational study
research Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis
research 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
research Supplementary Material for: Case report - Hair shaft normalization and hair growth in SPINK5-syndromic epidermal differentiation disorder (Netherton syndrome) while on treatment with dupilumab: a novel therapeutic approach for Trichorrhexis invaginata
This case report discusses a 67-year-old woman with Netherton syndrome (NS), a genetic disorder characterized by skin inflammation and hair defects, specifically Trichorrhexis invaginata (TI). The patient was treated with dupilumab, a biologic known for addressing cutaneous inflammation. After 3 months, the patient experienced significant improvements in skin rash, pruritus, and quality of life. Notably, the treatment led to the normalization of hair shafts and promoted hair growth, resolving the "bamboo" hair characteristic of TI. This case highlights dupilumab's potential in addressing hair abnormalities associated with NS, an area not extensively covered in current literature.
research Supplementary Material for: Case report - Hair shaft normalization and hair growth in SPINK5-syndromic epidermal differentiation disorder (Netherton syndrome) while on treatment with dupilumab: a novel therapeutic approach for Trichorrhexis invaginata
This case report discusses a 67-year-old woman with Netherton syndrome (NS), a genetic disorder characterized by skin inflammation and hair defects, specifically Trichorrhexis invaginata (TI). The patient was treated with dupilumab, a biologic known for addressing cutaneous inflammation. After 3 months, the patient experienced significant improvements in skin rash, pruritus, and quality of life. Notably, the treatment led to the normalization of hair shafts and promoted hair growth, resolving the "bamboo" hair characteristic of TI. This case highlights dupilumab's potential in addressing hair abnormalities associated with NS, an area not extensively covered in current literature.
research Case report - Hair shaft normalization and hair growth in SPINK5-syndromic epidermal differentiation disorder (Netherton syndrome) while on treatment with dupilumab: a novel therapeutic approach for Trichorrhexis invaginata
This case report discusses a 67-year-old woman with Netherton syndrome, a genetic disorder causing skin inflammation and hair defects like Trichorrhexis invaginata. The patient was treated with dupilumab, which is typically used for skin inflammation. After 3 months, there was significant improvement in skin symptoms and hair condition, with brittle "bamboo" hairs being replaced by normal hair shafts. This suggests that dupilumab may not only help with skin issues but also promote hair growth in Netherton syndrome, highlighting a novel therapeutic approach for addressing hair shaft abnormalities linked to inflammatory responses.
research 089 Single-cell RNA sequencing defines molecular similarities between patch/plaque-stage mycosis fungoides and atopic dermatitis under dupilumab
research New developments in the molecular treatment of ichthyosis: review of the literature
New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.
research Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
Baricitinib is the most effective treatment for alopecia areata.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
research Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.
research A clinician’s guide to pediatric and adolescent alopecia areata treatments
Topical corticosteroids are recommended first for treating pediatric alopecia areata due to their safety and ease of use.
research Drug-induced alopecia areata: A systematic review
Certain drugs can cause hair loss, but stopping the drug usually leads to hair regrowth.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
research Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis
Certain drugs can cause eyelid inflammation, so doctors should monitor and educate patients on eyelid care.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Alopecia areata: from pathophysiology to therapeutic innovation
JAK inhibitors are effective treatments for alopecia areata.
research New Modalities in the Treatment of Refractory Alopecia Areata
New treatments focusing on immune pathways show promise for stubborn hair loss.
research Severe Psoriasis Leading to Scarring Alopecia of the Scalp Responding to Biologic Therapy
Bimekizumab can improve scarring alopecia in severe psoriasis.
research Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
research The patient journey in prurigo nodularis: what lies ahead
Prurigo nodularis is hard to diagnose and treat, but new biologics offer hope for better management.
research Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.
research Combination of Netherton Syndrome and Hypopituitarism with Isolated Somatotropin Deficiency: Case Study
Treating Netherton syndrome with growth hormone and dupilumab improves growth safely.